TP53 and head and neck squamous cell carcinoma: Clinically, TP53 mutations are strongly correlated with reduced overall survival and increased resistance to radiotherapy and chemotherapy in patients with HNSCC, highlighting TP53 mutation status as a potentially valuable biomarker for risk stratification and prediction of therapeutic response in this population [28].